IDEAYA Biosciences今日正式宣布，其候选药物IDE892——一种被视作具有“同类最佳”（best-in-class）潜力的MTA协同PRMT5抑制剂——已启动1/2期临床研究的第二部分单药扩展阶段。该研究聚焦于MTAP基因缺失的胰腺癌和肺癌患者。
这一里程碑式的进展，标志着IDEAYA在精准肿瘤学领域迈出了关键一步。IDE892靶向的是一种在多种肿瘤中因MTAP缺失而尤为脆弱的代谢通路，旨在为这类特定基因背景的患者提供更高效、更具选择性的治疗选择。
此次启动的单药扩展部分，将在一系列经过严格筛选的MTAP缺失肿瘤患者中，进一步评估IDE892的安全性、耐受性及初步抗肿瘤活性。IDEAYA公司表示，基于前期临床数据，IDE892展现出令人鼓舞的潜力，有望改变当前MTAP缺失癌症的治疗格局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.